Sinary The photonecrotic effectveness of a morpholinothiolporphyn derived from haematoporphyrm was measured in an animal model of cerebral glioma. The dose administered was 20 mg kg-' and the laser dose varied from 0 to 200 J cm2. The tumour nerosis was at least as good as that of HpD, and this therapeutic response may be attributed to the targeting of specific 'photopotent' subcellular sites.
Photodynamic therapy (PDT) is a bimodal therapy comprising the enhanced uptake and retention of particular sensitisers by tumour tissue followed by light-induced destruction (Lipson et al., 1961; Gomer & Dougherty, 1979) . Certain tumours offer great suitability to be treated successfully using PDT in conjunction with surgery. Brain tumours are especially suited to PDT sine conventional treatments fail (Kaye & Hill, 1992) as a result of local recurrence of the tumour, suggesting that a therapy which targets the nonresectable tumour margin and invasive nests of tumour cells is appropriate.
One major reason for the effectiveness of PDT is the extent of localisation that can be achieved within intracranial tumours, owing mainly to the breakdown of the blood-brain barrier within tumour regions and the retention of an intact blood-brain barrier in normal brain (Kaye et al., 1985) . Tumour death is proposed to occur primarily through damage generated by the production of singlet oxygen and, since the reactive species is restricted by its short lifetime to a distance of 0.1 gm (Moan et al., 1979) , organelle-targeting photosensitisers may therefore increase the efficacy of PDT.
At present, haematoporphyrin derivative (HpD) and the more hydrophobic and purified form, Photofrin II, are the experimentally and clinically most frequently used photosensitisers (Kaye et al., 1988) . HpD phototherapy has produced encouraging results (Kaye, 1989; Kaye & Hill 1992) , but an alternative photosensitiser is desirable as HpD is a poorly defined mixture of porphyrins (Dougherty, 1987) . In order to establish the optimal structural characterstics of photosensitsers required for PDT, we recently synthesised and tested a series of porphyrin analogues (Woodburn et al., 1922a-c) . From this series MTP [7,12-bis(l-(2-morpholinoethanethiol) ethyl)-3,8,13,17-tetramethyl-21H,23H-porphyrin-2,18-dipropanoic acid, Figure 1] The method for establishing intracranial tumours was that developed by Kaye et al. (1985) .
Porphyrins
Haematoporphyrin derivative (HpD) was obtained from the Pharmacy Department, Queen Elizabeth Hospital (Adelaide, South Australia), and was the same preparation as used clinically by Kaye (Hill et al., 1990) in the treatment of human glioma. MTP was prepared from haematoporphyrin (Roussel UCLAF, Sydney, Australa). The synthesis and characterisation will be presented elsewhere. Purity was >99% as established by analytcal high-performance liquid chromatography (HPLC), and the structure was confirmed by infrared, 'H and '3C nuclear magnetic resonance (NMR) and electrospray mass spectrometry.
Photodyninic therapy
The rats were injected, intravenously via the femoral vein, with either MTP or HpD (20mg kg-') 9 days post inoculation of the C( glioma cells. injection of the porphyrin in a manner similar to that described by Kaye et al. (1985) , except that irradiation was with light of 628 nm from a gold metal vapour laser (Quentron, Adelaide, South Australia). The light was delivered through a quartz fibre (600 pm inner core diameter), which was placed in an integrating sphere with attached power meter. This enabled a calculation of the total energy administered (J cm-) to the craniotomy site. The fibre tip was held at a distance of 3-4mm over the area of the craniotomy so that emitted red light evenly covered the exposed tumour. The laser power at the fibre tip was kept at 1 W, and light was delivered at a dose of 0, 50, 100 or 200 J cm-2 ( Kaye et al., 1985) . The surface of the brain was irrigated with isotonic saline solution kept at room temperature during irradiation so as to prevent thermal damag to tumour or normal tissue. On completion of irradiation a single layer of Surgicel (Johnson & Johnson, North Ryde, New South Wals, Austalia) was used to cover the craniotomy site and the wound was closed with clips.
The animals were sacrificed 5 days after PDT treatment. The brains were removed, fixed in 10% formaldehyde, sectioned through the area of irradiation and stained with haematoxylin and eosin. The extent of cerebral necrosis was measured on serial sections using a graticule micrometer (Leitz, Wetzlar, Germany) as previously described by Kaye and Morstyn (1987) .
Resits
The in vivo model used produced intracranial tumours greater than 5 mm in diameter in 90% of the animals at 21 days when C6 cells (105) MTP is an impressive tumour photosensitiser, and the observed tumour necrosis compares favourably with HpD (Table I) . Like HpD, no photonecrosis was observed in normal brain using these light doses. MTP produced similar tumour kill at all light doses studied, and at a dose of 1OOJcm-2 the depth of tumour necrosis was 3.6mm compared with 2.8 mm for HpD. At 200 J cm-2 extensive tumour kill was observed with MTP, while almost complete kill was observed with HpD.
The similar photosensitising effectiveness of MTP and HpD observed in this study may be due to a variety of previously studied factors (an increase in lipophiicity with decreasing pH; facile in vitro dark cytotoxicity and potent phototoxicity values; discrete subcellular localisation sites, and high localising propensity in tumour tissue compared with the surrounding normal brain tissue). Photosensitisers that exhibit an increase of lipophilicity with decreasing pH have been shown to be retained more in tumour tissue than those compounds which exhibit other trends (Moan et al., 1987) . Both MTP and HpD exhibit increasing partition coefficients with decreasing pH (Woodburn et al., 1992b) . 
Dark cytotoxicity and phototoxicity values for MTP and
HpD were determined in in vitro cultures of C6 glioma cells (Woodburn et al., 1992a) . The ID_v for HpD was 17.511M
and for MTP 90 FM, where the ID_, is the dose required for 50% inhibition of colony survival in the dark. MTP was more effective than HpD in mediating cell death in vitro. The IT,, for HpD was 45 mi, and for MTP it was 12 mi, where the IT,o is defined as the time required for 50% inhibition of colony survival when exposed to red light at a level equivalent to the ID,. MTP displayed a selective tumour localisation (Woodburn et al., 1992b) in the murine C6 glioma model. The tumour uptake determined at 6 and 24 h post injection was 10.2 and 6.2 gg-' respectively for HpD, and 11.7 and 7.2JAgg-I respcively for MTP. Since the site of photosensibser localisation within the tumour mass is thought also to represent the site of photodamage (Moan et al., 1979) , subceliular distribution studies provide some indication of the relative effectiveness of a particular photosensitser. MTP distibutes in the lysosomes of C6 glioma cells, while HpD displays diffuse cytoplasmic plus perinuclear staining of the cells (Woodburn et al., 1991) . In vitro lysosomes offer a more effective photodynamic target than diffuse sites within the cytoplasm. In vivo photosensitisation of lysosomes may result in organelie rupture with the release of hydrolytic enzymes which have the potential to kill cells and surrounding tissue (Allison et al., 1966; von Ardenne & Kruger, 1979) . The clinical effectiveness of PDT depends upon the determination of factors such as sensitiser and light, the dosage administered, tumour uptake and tissue distribution of the photosensitiser. In this study the photonecrotic effectiveness of MTP was measured in the rat C6 intracerebral glioma model. MTP, a pure compound that is less toxic than HpD and has a good tumour localising capacity, was at least as good as HpD in eliciting tumour death. Future design of prospective photosensitisers for use in PDT can therefore be based upon this chemically pure compound (in contrast to the range of components in HpD) and offers the chance to develop struture-activity relationships for this type of photosensitiser that appears to target specific organelles.
Abbreviato
MTP, (7,12-bis(1-(2-morpholinoethanethiol) 
